Yeah, I believe kol's were not convinced because they didnt consider erlotinib standard of care when study finished. At the time it was said they would follow up with more studies.
Here is OS results from that study.
Overall survival was also improved with cabozantinib. The cabozantinib monotherapy group had a median overall survival of 9.2 months, compared with 5.1 months with erlotinib (HR, 0.68; 95% CI, 0.49–0.95; P = .071). The combination group had a median overall survival of 13.3 months (HR, 0.51; 95% CI, 0.35–0.74; P = .011). Objective response rates were similar across the groups.
The new study’s authors plan to follow up with a study of cabozantinib involving a non-erlotinib control group, to “further delineate a role for cabozantinib in the treatment of advanced non-squamous NSCLC.”